+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Histamine H4 Receptor - Pipeline Review, H2 2020

  • ID: 5189136
  • Drug Pipelines
  • October 2020
  • Region: Global
  • 48 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Bioprojet SCR
  • Chrysalis Pharma SAS
  • JW Pharmaceutical Corp
  • Sensorion SA
  • Sosei Heptares
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

According to the recently published report 'Histamine H4 Receptor - Pipeline Review, H2 2020'; Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 6 molecules.

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.

The report 'Histamine H4 Receptor - Pipeline Review, H2 2020' outlays comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 1 and 4 respectively. Report covers products from therapy areas Dermatology, Ear Nose Throat Disorders, Immunology, Ophthalmology and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Sensorineural Hearing Loss, Age Related Macular Degeneration, Allergic Conjunctivitis, Allergies, Cystic Fibrosis, Hearing Disorders and Idiopathic Pulmonary Fibrosis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bioprojet SCR
  • Chrysalis Pharma SAS
  • JW Pharmaceutical Corp
  • Sensorion SA
  • Sosei Heptares
Introduction
  • Report Coverage
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development
  • Bioprojet SCR
  • Chrysalis Pharma SAS
  • JW Pharmaceutical Corp
  • Sensorion SA
  • Sosei Heptares
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles

azasetron - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
BPI-7881A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
JWP-1601 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Antagonize H4 Receptor for Atopic Dermatitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 16, 2020: Sensorion hosting key opinion leader call with Dr. Michael Hoffer on sudden sensorineural hearing loss and SENS-401 as a Potential Treatment Option on July 23, 2020
  • Mar 16, 2020: Covid-19: Sensorion delays Phase ll trial due to slow recruitment rate
  • Feb 18, 2020: Sensorion gets approval to add new sites to Phase II trial of SENS-401
  • Feb 03, 2020: Sensorion to attend and present at LSX World Congress 2020
  • Jan 30, 2020: Sensorion presents new SENS-401 preclinical data at ARO Midwinter Meeting 2020
  • Jan 10, 2020: Sensorion announces its presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference
  • Dec 23, 2019: Sensorion announces positive data safety monitoring board review of Phase 2 trial for SENS-401 in Sudden Sensorineural Hearing Loss
  • Dec 23, 2019: Sensorion announces €5.6m non-dilutive funding to support SENS-401 Phase 2 study in Sudden Sensorineural Hearing Loss French ministry of armed forces to participate in the study
  • Nov 20, 2019: Drug tested for sudden hearing loss
  • Nov 07, 2019: Sensorion announces an oral presentation of new SENS-401 preclinical data at ISIET 2019 in Hannover
  • Oct 23, 2019: Sensorion announce collaboration announces a poster presentation of new SENS-401 preclinical data at SFN 2019 in Chicago
  • Sep 11, 2019: Sensorion announces three presentations at IEB 2019 in Padua
  • Aug 27, 2019: LEO Pharma files IND application to FDA for a clinical study of JW1601/LP0190 in the US
  • Jul 11, 2019: Sensorion receives FDA IND Approval for Arazasetron (SENS-401)
  • Jun 28, 2019: Sensorion’s PIP is EMA-approved for two indications
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Bioprojet SCR, H2 2020
  • Pipeline by Chrysalis Pharma SAS, H2 2020
  • Pipeline by JW Pharmaceutical Corp, H2 2020
  • Pipeline by Sensorion SA, H2 2020
  • Pipeline by Sosei Heptares, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Dormant Products, H2 2020 (Contd..2), H2 2020
  • Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bioprojet SCR
  • Chrysalis Pharma SAS
  • JW Pharmaceutical Corp
  • Sensorion SA
  • Sosei Heptares
Note: Product cover images may vary from those shown
Adroll
adroll